Jonathan Schwartz
Chief Tech/Sci/R&D Officer bij ROCKET PHARMACEUTICALS, INC.
Vermogen: 5 M $ op 31-03-2024
Profiel
Jonathan David Schwartz is currently the Chief Medical & Gene Therapy Officer at Rocket Pharmaceuticals, Inc. He previously worked as the Vice President-Clinical Science at Eli Lilly & Co. and as the Vice President-Clinical Development at Stemline Therapeutics, Inc. from 2014 to 2016.
He also held the position of Associate Professor at The Mount Sinai Medical Center, Inc. and Chief Medical Officer & Head-Clinical Development at Rocket Pharmaceuticals Ltd.
Dr. Schwartz obtained a doctorate degree from Washington University in St. Louis and an undergraduate degree from Brown University.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
25-03-2024 | 172 413 ( 0.19% ) | 5 M $ | 31-03-2024 |
Actieve functies van Jonathan Schwartz
Bedrijven | Functie | Begin |
---|---|---|
ROCKET PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 26-03-2024 |
Eerdere bekende functies van Jonathan Schwartz
Bedrijven | Functie | Einde |
---|---|---|
STEMLINE THERAPEUTICS, INC. | Corporate Officer/Principal | 01-01-2016 |
Rocket Pharmaceuticals Ltd.
Rocket Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Rocket Pharmaceuticals Ltd. operates as a biotechnology company which focuses on developing gene therapy treatment for undertreated diseases. The firm’s pipeline includes Fanconi Anemia, Pyruvate Kinase Deficiency, Leukocyte Adhesion Deficiency-1 and Infantile Malignant Osteopetrosis. It also develops an AAV-based therapy program for an undisclosed rare pediatric disease. The company is headquartered in New York, NY. | Chief Tech/Sci/R&D Officer | - |
ELI LILLY AND COMPANY | Corporate Officer/Principal | - |
The Mount Sinai Medical Center, Inc.
The Mount Sinai Medical Center, Inc. Hospital/Nursing ManagementHealth Services The Mount Sinai Medical Center, Inc. operates charitable teaching hospitals. The non-profit company is based in New York, NY. The CEO of the company is Gino Santorio. | Corporate Officer/Principal | - |
Opleiding van Jonathan Schwartz
Washington University in St. Louis | Doctorate Degree |
Brown University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
ELI LILLY AND COMPANY | Health Technology |
ROCKET PHARMACEUTICALS, INC. | Health Technology |
Bedrijven in privébezit | 3 |
---|---|
Stemline Therapeutics, Inc.
Stemline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY. | Health Technology |
The Mount Sinai Medical Center, Inc.
The Mount Sinai Medical Center, Inc. Hospital/Nursing ManagementHealth Services The Mount Sinai Medical Center, Inc. operates charitable teaching hospitals. The non-profit company is based in New York, NY. The CEO of the company is Gino Santorio. | Health Services |
Rocket Pharmaceuticals Ltd.
Rocket Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Rocket Pharmaceuticals Ltd. operates as a biotechnology company which focuses on developing gene therapy treatment for undertreated diseases. The firm’s pipeline includes Fanconi Anemia, Pyruvate Kinase Deficiency, Leukocyte Adhesion Deficiency-1 and Infantile Malignant Osteopetrosis. It also develops an AAV-based therapy program for an undisclosed rare pediatric disease. The company is headquartered in New York, NY. | Health Technology |